Anticoagulant
Anticoagulant
Anticoagulant
By Dr Ayesha Afzal
CLASSIFICATION
INDIRECT THROMBIN INHIBITORS Unfractionated Heparin Low molecular weight Heparins Enoxaparin Dalteparin Fondaparinux DIRECT THROMBIN INHIBITORS Hirudin Lepirudin Argatroban Dabigatran
VITAMIN K ANTAGONISTS Coumarin Derivatives Warfarin , Dicoumarol Nicoumalone , Acenocumarol Indandione Derivatives Phenindione, Diphenindione, Anisindione. CALCIUM CHELATORS K- Oxalate K- Citrate Na Citrate EDTA (Etmylene Diamine Tetra Acetic Acid)
HEPARIN - CHEMISTRY
Heparin consists of Heterogenous group of straight chain anionic mucopolysaccharides of molecular weights that average 15000. Commercial heparin consists of polymers of two repeating sulphated disaccharide units. These are D-glucosamine-Liduronic acid and D-glucosamine-D-glucuronic acid.
PHARMACOKINETICS
Heparin
Standard Heparin or Unfractioned Heparin (UFH) MW 5000-30000
Low MW Forms of Heparin preparations (2000-6000 MW) Enoxaparin Tinzaparin Dalteparin Fondaparinux
Heparin Doses:Treatment of Coronary / Thrombosis/ Thromboembolism 5000 10,000 Units I/V bolus then 1000 U/hr 10,000 U bolus, then 5000-10,000 U 4 hrly Intermittently 1/V Major Surgery for prevention of Thromboembolism S/C dose 5000 units 2 hours before major operation followed by 5000 units 8 hrly for 7 14 days. Low dose (Minihep) 5000U S/C
THERAPEUTIC USES
1. To depress clotting during the first 36 - 48 hours of oral anticoagulant therapy for the treatment of venous thrombosis and pulmonary embolism or may be employed as the sole anticoagulant for a longer period in pts who experience recurrent thromboembolism despite adequate oral anticoagulant therapy e.g. Trousseaus syndrome. 2. To prevent clotting during open heart surgery (cardiopulmonary bypass) 3. To prevent clotting during Haemodialysis. 4. Acute myocardial infarction.
5.
6. 7.
In combination with thrombolytics for revascularization and in combination with glycopotein IIb/IIIa inhibitors during angioplasty and placement of coronary stents Drug of choice in pregnancy when an anticoagulant must be used. Low- dosage Heparin used in preventing post operative DVT (Deep Venous Thrombosis) and Pulmonary Embolism.
8.
To Prevent Venous Thrombosis during pregnancy and puerperium for 5-6 weeks after delivery. 9. Used intraperitoneally during Peritoneal Dialysis. 10. To clear intravascular cannulae. 11. DIC 12. To preserve blood in vitro.
ADVERSE EFFECTS
Overdose may cause bleeding. A painful, blue-ting discoloration of the planter surfaces and sides of toes. Thrombocytopenia Transient Alopecia Diarrhoea Allergic Reactions: Urticaria, Asthma and Anaphylactic shock. Osteoporosis leading to spontaneous vertebral fractures.
Thrombosis in very high doses due to depletion of antithrombin-III. Abnormalities in liver functions Skin lesions at the site of SC injections
ANTIDOTE
Protamine sulphate obtained from Salmon sperm Heparin
1% solution given I / V.
For each Heparin (100U) 1 mg of Protamine sulphate. LMWH
CONTRAINDICATIONS
1. 2. 3. 4. 5. 6. 7.
Hypersensitivity to the drug Haemophilia Thrombocytopaenia Purpura Severe hypotension Intracranial Haemorrhage Infective endocarditis
8. Active TB 9. Ulcerative lesions of GIT 10. Threatened Abortion 11. Visceral Carcinoma 12. Advance Hepatic & Renal disease 13. Recent operation on Eye, Brain & Spinal
Cord 14. During Lumbar Puncture
ORAL ANTICOAGULANTS
WARFARIN Na PHENINDIONE
CHEMISTRY
WARFARIN
PHARMACOKINETICS
Control
I One stage Prothrombin Time
Ratio of the Prothrombin Time of patients III plasma to the Prothrombin Time of control plasma being kept at 2.5 3.5
II INR =
PT pt
PT ref
ISI
ADVERSE EFFECTS
Bleeding Skin rashes Blood dyscrasias, Jaundice, Pyrexia, Nausea & Vomiting, Anorexia Pregnancy-produce Fetal and Neonatal bleeding Depression of Bone Formation Cutaneous necrosis due to decreased synthesis of Protein C Infarction of breast, Necrosis of fatty tissue, intestines and extremities Alopecia
ANTIDOTE
Phytonadione Dose : 10 25 mg slow I/V. Neonates 1mg slow I/V. Severe cases of bleeding:Phytonadione IV+ Fresh Frozen Plasma I/V. rVII
INTERACTIONS
Increased Sensitivity to Oral Anticoagulants 1. Displacement of anticoagulant from its binding
to plasma protein.
Phenylbutazone and numerous NSAIDs Sulphonamides, Co-trimoxazole Oral anti-diabetic agents Ethacrynic acid Mefenamic acid Nalidixic acid Aspirin and numerous non-steroidal antiinflammatory agents may also interfere with platelet function and prolong the bleeding time.
o Coumarin Derivative
o Small lipid soluble molecule o Semi-Synthetic
O Liver o Oral
Onset of action:
o Quick (in seconds)
Duration of Action
o Short (10 15 min)
Protein Binding
o Nil heparin but not for LMM heparins o Extensive
Metabolites
o Uroheparin Half Life 40-90 Min
OS.Warfarim-7Hydroxy warfarin, o R.Warfarin- Warfarin alcohol
15-70 hrs
HEPARIN
a. Acts by activating Antithrombin o Inhibits Vit K dependent III, forming a complex with synthesis of factor II, VII, IX Antithrombin III & activated and X in the liver by inhibiting factors IXa, XIa, Xa, XIIa, XIIIa , gamma-carboxylation of glutamate resides in the above mentioned accelerating the activity of factors, by inhibiting the enzyme vit Antithrombin III to inactivate the K Epoxide reductase. above factors & thrombin. b. Vasodilator c. Acts like Lipemic Plasma clearing factor o Nil o Nil
HEPARIN
WARFARIN O MI O D.V.T o Pulmonary Embolism o CVA o Atrial Fibrillation o Cardiac surgery with artificial valves implantation o Bleeding, Fetal bleeding o Fetal bone formation depressed o Protein C inhibition with issue necrosis o Interaction with enzyme inhibitors and inducers
Therapeutics Uses
o Open Heart surgery, o Perimtoneal dialysis, o Haemodialysis, D.V.T and Pulmonary Embolism o Acute M I o Pregnancy, Puerperium o DIC
Adverse Effects
o Bleeding o Allergic reactions o Diarrhea osteoporosis o Alopecia